Cambridge, Massachusetts, Feb. 04, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing next-generation therapies for Alzheimer’s ...
Cambridge, Massachusetts, Feb. 04, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing next-generation therapies for Alzheimer's ...
Cambridge, Massachusetts, Feb. 04, 2026 (GLOBE NEWSWIRE) — ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing next-generation therapies for Alzheimer’s disease ...
(RTTNews) - ProMIS Neurosciences Inc. (PMN), a clinical-stage biotechnology company, has announced on Friday a private investment in public equity financing of up to approximately $175 million. The ...
CAMBRIDGE, Mass. - ProMIS Neurosciences Inc. (NASDAQ:PMN) has entered into a securities purchase agreement with institutional and accredited investors to raise up to $175 million through a private ...
Investing.com -- ProMIS Neurosciences Inc. (NASDAQ:PMN) stock soared 24% after the clinical-stage biotechnology company announced it has entered into a securities purchase agreement for a private ...
CAMBRIDGE, Massachusetts , Jan. 30, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN) (“ProMIS” or the “Company”), a clinical-stage biotechnology company focused on the generation and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results